Biodesix Inc BDSX

$21.18 -2.76 (-11.53%)

Valuation

Market cap
223,470,000
Revenue TTM
$88,500,000
Net income TTM
$-35,270,000
PE ratio
0.00
Forward PE
—
Profit margin
-39.85%
Debt to equity
5.12

Trading

Volume
139,700
Avg volume
107,138
Day's range
$21.11 – $23.70
Shares out
10,551,000
Stochastic %K
2%
Beta
0.56
Analysts
Strong Sell
Price target
$39.00

Price

Company profile

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR...

Show more

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
303 417 0500
Website
https://www.biodesix.com
Address
919 West Dillon Road, Louisville, United States

Latest news

Stocktwits

healthcareguru Oct 23, 2:36 PM
$BDSX BUYER. See you at $100. 🦾 $XBI
0 replies
focafoca99 Oct 22, 10:24 AM
$BDSX plans to release its Q3 2026 results on Nov 5.
0 replies
healthcareguru Oct 21, 4:36 PM
$BDSX Time to get to work guys…beat/raise on deck vs dirt cheap valuation and M&A target. Easily going back >$30 and will be $100 in 18-24mos. Buying time. 😍🦾 $XBI $XLV $IWM
0 replies
focafoca99 Oct 19, 10:16 AM
$BDSX added a digital diagnostics platform to its lung portfolio, debuting a radiomics test for nodule risk assessment.
0 replies
healthcareguru Oct 14, 5:40 PM
$BDSX dumb move…buying daily. This will be a $100 stock in 18-24mos and is a clear M&A target. Premier >20% growth, inflecting profitability, huge TAM, vs dirt cheap valuation at only ~2x 2027e EV/sales vs peer group at 4-8x. BUYER! 😍🦾 $XLV $IWM $XBI $GH
0 replies
healthcareguru Sep 28, 5:41 PM
$BDSX $100 …volume spiking 🔥🦾 $XBI $IWM $XLV
0 replies
healthcareguru Sep 24, 5:25 PM
$BDSX this is going to $100… 🔥🔥 $XBI $IWM $XLV $GRAL
0 replies
focafoca99 Sep 24, 10:22 AM
$BDSX launched two complementary MRD programs with Bio-Rad and Thermo Fisher, expanding its cancer-monitoring portfolio.
0 replies